Dynamic placenta-on-a-chip model for fetal risk assessment of nanoparticles intended to treat pregnancy-associated diseases

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

卷:1867

Review

Shojaei, Shahla¹  Ali, Moustafa S.^1,2  Suresh, Madhumita¹  Upreti, Tushar¹  Mogourian, Victoria¹  Helewa, Michael³  Labouta, Hagar, I^1,2,4,5 

[1] Univ Manitoba, Coll Pharm, Rady Fac Hlth Sci, Winnipeg, MB, Canada

[2] Univ Manitoba, Childrens Hosp, Res Inst Manitoba, Winnipeg, MB, Canada

[3] Univ Manitoba, Dept Obstet Gynecol & Reprod Sci, Winnipeg, MB, Canada

[4] Univ Manitoba, Biomed Engn, Winnipeg, MB, Canada

[5] Alexandria Univ, Fac Pharm, Alexandria, Egypt

关键词: Nanoparticles;    Prenatal therapy;    Microfluidics;    Fetus;    Placenta;    Pregnancy;   

DOI  :  10.1016/j.bbadis.2021.166131

来源: Elsevier

【 摘 要 】

Pregnant women often have to take medication either for pregnancy-related diseases or for previously existing medical conditions. Current maternal medications pose fetal risks due to off target accumulation in the fetus. Nanoparticles, engineered particles in the nanometer scale, have been used for targeted drug delivery to the site of action without off-target effects. This has opened new avenues for treatment of pregnancy-associated diseases while minimizing risks on the fetus. It is therefore instrumental to study the potential transfer of nanoparticles from the mother to the fetus. Due to limitations of in vivo and ex vivo models, an in vitro model mimicking the in vivo situation is essential. Placenta-on-a-chip provides a microphysiological recapitulation of the human placenta. Here, we reviewed the fetal risks associated with current therapeutic approaches during pregnancy, analyzed the advantages and limitations of current models used for nanoparticle assessment, and highlighted the current need for using dynamic placenta-on-a-chip models for assessing the safety of novel nanoparticle-based therapies during pregnancy.

【 授权许可】

Free